Fig. 3: Monitoring the therapeutic efficacy of 188Re-liposome administrated in HNSCC tumor-bearing mice with different regimes. | Cell Death Discovery

Fig. 3: Monitoring the therapeutic efficacy of 188Re-liposome administrated in HNSCC tumor-bearing mice with different regimes.

From: PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial–mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy

Fig. 3

a Reporter gene imaging of tumor growth responding to a single dose, repeated doses of 188Re-liposome, and untreated control (n = 5). b Quantification of BLI signals. c Caliper measurement of tumor volumes (n = 5). Data were represented as means ± S.D. *p < 0.05 by an unpaired two-tailed t-test. d Representative photos of excised orthotropic tumors. e Analysis of animal survival using the Kaplan–Meier method with log-rank test (p < 0.001)

Back to article page